Contribution of modelization to our knowledge of the spread of infectious diseases and their prevention;Apport de la modélisation à la connaissance de la diffusion des maladies infectieuses et de leur prévention

Revue d'Epidemiologie et de Sante Publique

Volumn 54, Issue 2, 2006, Pages 105-109

  Desenclos, J C ^a  

^a INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE; VACCINE; WART VIRUS VACCINE;

BIOLOGICAL WARFARE; BRAIN SPONGIOSIS; CREUTZFELDT JAKOB DISEASE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER CANCER; MODEL; NONHUMAN; PROPHYLAXIS; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 33646684723     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-7620(06)76703-7     Document Type: Editorial

References (32)

1. Bernouilli D. http://fr.wikipedia.org/wiki/Daniel_Bernoulli (Consulté le 28 janvier 2006).
2. Hamer WH. Epidemic disease in England-the evidence of variability and of resistance of type. Lancet 1996; 2:733-9.
3. Kermack WO, McHendrick AG. Contributions to the mathematical theory of epidemics. Part I. Proc R Soc A 1927; 115: 700-21
4. (Bull Math Biol 1991; 53: 33-55).
5. Kermack WO, McHendrick AG. Contributions to the mathematical theory of epidemics. Part II - The problem of endemicity. Proc R Soc A 1932; 138: 55-83
6. (Bull Math Biol 1991; 53: 57-87).
7. Kermack WO, McHendrick AG. Contributions to the mathematical theory of epidemics. Part III - Further studies of the problem of endemicity. Proc R Soc A 1933; 141: 94-122
8. (Bull Math Biol 1991; 53: 89-118).
9. nd Edition, with an addendum on the theory of happenings. London John Murray, 1911.
10. MacDonald G. The epidemiology and control of malaria. Oxford: Oxford University Press, 1957.
11. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
12. Fine P. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15: 265-302.
13. Halloran EM, Lipsitch. Infectious disease modeling contributions to the American Journal of Epidemiology. Am J Epidemiol 2005; 161: 997-8.
14. Ramsay M, Gay N, Miller E. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. CDR Rev 1994; 4: R141-6.
15. Lévy-Bruhl D, Macario J, Richardson S, Guérin N. Modélisation de la rougeole en France et conséquences pour l'âge de la seconde vaccination rougeoleoreillons-rubéole. Bull Epidemiol Hebdo 1997; 29: 133-5.
16. Anderson RM, Grenfell BT. Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom. J Hyg Camb 1986; 96: 305-33.
17. World Health Organization Writing Group. Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg Infect Dis (serial on the Internet) 2006 January (date cited). Available from http://www.cdc.gov/ncidod/ EID/vol12no01/05-1370.htm (Consulté le 28 janvier 2006).
18. Valleron AJ, Boelle P-Y, Chatignoux E, Cesbron JY. Can a second wave of new variant of the CJD be discarded in absence of observation of clinical non Met-Met cases? Rev Epidemiol Sante Publique 2006; 54:111-5.
19. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
20. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9.
21. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005; 437: 209-14.
22. Gani R. Potential impact of antiviral drug use during influenza pandemic. Emerg Infect Dis 2005; 11: 1355-62.
23. Longini IM, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004; 159: 623-33.
24. Longini IM, Nizam A, Xu S, Ungchusak K, Handshoworakul W, Halloran ME. Containing pandemic influenza at the source. Science 2005; 309(5737): 1083-7.
25. Doyle AM, Bonmarin I, Lévy-Bruhl D, Le Strat Y, Desenclos JC. Influenza pandemic preparedness in France: modelling the impact of interventions. J Epidemiol Community Health 2006 (in press).
26. Kaplan EH, Craft DL, Wein LM. Emergency responses to s smallpox attack: the case for mass vaccination. PNAS 2002; 99: 10935-40.
27. Halloran ME, Longini IM, Nizan A, Yang Y. Containing bioterrorist smallpox. Science 2002; 298: 1428-32.
28. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9.
29. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125: 651-69.
30. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-26.
31. Raboud J, Saskin R, Simor A, Loeb M, Green K, Low DE, et al. Modelling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol 2005; 26: 607-15.
32. Antia R, Regoes RR, Koella JC, Bergstrom CT. The role of evolution in the emergence of infectious diseases. Nature 2003; 426: 658-61.